SCHEMBL2865257

SCHEMBL2865257

CCn1ccc(C)nc1=O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.40
LMNA P02545 3/20 0.40
MEN1 O00255 3/20 0.40
ABCC4 O15439 1/20 0.40
PKM P14618 1/20 0.40
PTGS1 P23219 1/20 0.40
MAPT P10636 4/20 0.39
SMN1; SMN2 Q16637 4/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 1/20 0.38
ATM Q13315 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DRD2 P14416 1/20 0.38
DRD3 P35462 1/20 0.38
HSD17B10 Q99714 3/20 0.38
CYP1A2 P05177 2/20 0.38
KDM4E B2RXH2 2/20 0.38
NFKB1 P19838 1/20 0.38
BLM P54132 1/20 0.38
POLB P06746 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1892698 0.78 FGFR1 (0.44) LMNAMAPTPIK3CDPIK3CAPIK3CB
SCHEMBL14872357 0.78 MAPT (0.35) KMT2ALMNAMAPTHSD17B10CYP1A2
SCHEMBL11249598 0.78 MAPT (0.35) KMT2AMAPTKDM4EALDH1A1PIK3CD
Hydrochloric Acid SCHEMBL6011092 0.77 HSD17B10 (0.51) KMT2ALMNAPKMMAPTSMN1; SMN2
SCHEMBL8768188 0.77 MAPT (0.49) KMT2ALMNAMEN1ABCC4PKM
SCHEMBL14450620 0.77 TSHR (0.38) KMT2ALMNAPKMMAPTSMN1; SMN2
SCHEMBL591865 0.74 DRD2 (0.44) KMT2ALMNAMAPTSMN1; SMN2RAB9A
SCHEMBL19746414 0.73 P2RX7 (0.46) KMT2ALMNAMEN1MAPTSMN1; SMN2
SCHEMBL14639242 0.73 MAPT (0.47) KMT2ALMNAMAPTL3MBTL1HSD17B10
SCHEMBL13223804 0.72 DRD2 (0.42) KMT2AMAPTDRD2DRD3ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022174253-A1 HPK1 ANTAGONISTS AND USES THEREOF Nimbus Saturn, Inc. (US) 2022-08-18 WO disclosed
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE GENENTECH, INC. (US) 2013-04-18 US disclosed
WO-2010046190-A2 TRICYCLIC ALDEHYDES AND C,H ACIDIC COMPOUNDS HENKEL AG & CO. KGAA (DE) 2010-04-29 WO disclosed
WO-2007015162-A1 PIPERIDINOYL-PYRROLIDINE AND PIPERIDINOYL-PIPERIDINE COMPOUNDS PFIZER LIMITED (GB) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096104-A1 IMIDAZOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE TYK2, IRAK1, IRAK4 KMT2A 2005/4885LMNA 2401/4885MEN1 4055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.